Trials / Unknown
UnknownNCT01484171
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 7 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | idarubicin | idarubicin 10-12 mg/m2 for three days |
| BIOLOGICAL | microtransplantation | idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2017-08-01
- Completion
- 2017-12-01
- First posted
- 2011-12-02
- Last updated
- 2016-07-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01484171. Inclusion in this directory is not an endorsement.